Minute Insight: Vicarious’ Future Gets Precarious
The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.
You may also be interested in...
He may not be Ali, but Butterfly Network's new CEO, Joseph DeVivo, believes Butterly’s microchip tech packs a formidable punch. He expects the company’s technology will help it transcend the market-development challenges the company faced under its previous leaderships.
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
The Belgian start-up is developing a scleral contact lens with an inbuilt LCD screen capable of filtering light – offering a non-surgical solution to a variety of ophthalmic conditions.